KR100783346B1 - 세로토닌 재흡수 억제제로서 페닐-피페라진 유도체 - Google Patents

세로토닌 재흡수 억제제로서 페닐-피페라진 유도체 Download PDF

Info

Publication number
KR100783346B1
KR100783346B1 KR1020067022562A KR20067022562A KR100783346B1 KR 100783346 B1 KR100783346 B1 KR 100783346B1 KR 1020067022562 A KR1020067022562 A KR 1020067022562A KR 20067022562 A KR20067022562 A KR 20067022562A KR 100783346 B1 KR100783346 B1 KR 100783346B1
Authority
KR
South Korea
Prior art keywords
phenyl
piperazine
acid
alk
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020067022562A
Other languages
English (en)
Korean (ko)
Other versions
KR20060118020A (ko
Inventor
토마스 룰란트
개릭 폴 스미스
베뉘 방-안데르센
아스크 퓌슐
아이네르 크누드 몰트센
킴 안데르센
Original Assignee
하. 룬트벡 아크티에 셀스카브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100783346(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 하. 룬트벡 아크티에 셀스카브 filed Critical 하. 룬트벡 아크티에 셀스카브
Publication of KR20060118020A publication Critical patent/KR20060118020A/ko
Application granted granted Critical
Publication of KR100783346B1 publication Critical patent/KR100783346B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1020067022562A 2001-10-04 2002-10-02 세로토닌 재흡수 억제제로서 페닐-피페라진 유도체 Expired - Lifetime KR100783346B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101466 2001-10-04
DKPA200101466 2001-10-04

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020047004897A Division KR100770194B1 (ko) 2001-10-04 2002-10-02 세로토닌 재흡수 억제제로서 페닐-피페라진 유도체

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020077022025A Division KR100842702B1 (ko) 2001-10-04 2002-10-02 세로토닌 재흡수 억제제로서 페닐-피페라진 유도체

Publications (2)

Publication Number Publication Date
KR20060118020A KR20060118020A (ko) 2006-11-17
KR100783346B1 true KR100783346B1 (ko) 2007-12-07

Family

ID=8160750

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020047004897A Expired - Lifetime KR100770194B1 (ko) 2001-10-04 2002-10-02 세로토닌 재흡수 억제제로서 페닐-피페라진 유도체
KR1020067022562A Expired - Lifetime KR100783346B1 (ko) 2001-10-04 2002-10-02 세로토닌 재흡수 억제제로서 페닐-피페라진 유도체
KR1020077022025A Expired - Lifetime KR100842702B1 (ko) 2001-10-04 2002-10-02 세로토닌 재흡수 억제제로서 페닐-피페라진 유도체

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020047004897A Expired - Lifetime KR100770194B1 (ko) 2001-10-04 2002-10-02 세로토닌 재흡수 억제제로서 페닐-피페라진 유도체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020077022025A Expired - Lifetime KR100842702B1 (ko) 2001-10-04 2002-10-02 세로토닌 재흡수 억제제로서 페닐-피페라진 유도체

Country Status (38)

Country Link
US (10) US7144884B2 (enExample)
EP (2) EP1436271B3 (enExample)
JP (3) JP3896116B2 (enExample)
KR (3) KR100770194B1 (enExample)
CN (1) CN1319958C (enExample)
AR (2) AR036659A1 (enExample)
AT (2) ATE441631T1 (enExample)
AU (2) AU2002333220C1 (enExample)
BE (1) BE2014C036I2 (enExample)
BR (3) BRPI0212733B8 (enExample)
CA (1) CA2462110C (enExample)
CO (1) CO5580746A2 (enExample)
CY (3) CY1107924T1 (enExample)
DE (2) DE60233608D1 (enExample)
DK (2) DK1749818T3 (enExample)
EA (2) EA007537B3 (enExample)
EG (1) EG25095A (enExample)
ES (2) ES2328725T3 (enExample)
FR (1) FR14C0033I2 (enExample)
HR (1) HRP20040220A2 (enExample)
HU (3) HU228956B1 (enExample)
IL (1) IL160655A0 (enExample)
IS (2) IS2578B (enExample)
LT (1) LTC1436271I2 (enExample)
LU (1) LU92397I2 (enExample)
ME (1) ME00039B (enExample)
MX (1) MXPA04002959A (enExample)
MY (1) MY140950A (enExample)
NL (1) NL300652I1 (enExample)
NO (3) NO326443B1 (enExample)
NZ (1) NZ531556A (enExample)
PL (2) PL210551B1 (enExample)
PT (2) PT1436271E (enExample)
RS (2) RS52326B (enExample)
SI (1) SI1436271T1 (enExample)
UA (2) UA81749C2 (enExample)
WO (1) WO2003029232A1 (enExample)
ZA (1) ZA200401583B (enExample)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
GB0305575D0 (en) * 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
SI1626720T1 (sl) * 2003-04-04 2008-12-31 Lundbeck & Co As H Derivati 4-(2-fenilsulfanil-fenil)-piperidina kotzaviralci ponovnega vnosa serotonina
UA81300C2 (en) * 2003-04-04 2007-12-25 Lundbeck & Co As H Derivates of 4-(2-fenilsulfanilfenil)-1,2,3,6-tetrahydropiridin as retarding agents of serotonin recapture
KR20050119682A (ko) * 2003-04-04 2005-12-21 하. 룬트벡 아크티에 셀스카브 세로토닌 재흡수 억제제로서 4-(2-페닐옥시페닐)-피페리딘또는 -1,2,3,6-테트라히드로피리딘 유도체
NZ541859A (en) * 2003-04-04 2008-10-31 Lundbeck & Co As H 4-(2-Phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
JP2006522027A (ja) * 2003-04-04 2006-09-28 ハー・ルンドベック・アクチエゼルスカベット セロトニン再取り込み阻害剤としての４−（２−フェニルオキシフェニル）−ピペリジンまたは−１，２，３，６−テトラヒドロピリジン誘導体
PT1701940E (pt) 2003-12-23 2008-07-30 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-benzil-amina como ssri
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
US7923444B2 (en) * 2005-02-10 2011-04-12 Neurosearch A/S Alkyl substituted homopiperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054393A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
JP2007106746A (ja) * 2005-09-13 2007-04-26 Tosoh Corp 新規アリールホモピペラジン類、またはその塩と製造方法
AR061480A1 (es) * 2006-06-16 2008-08-27 Lundbeck & Co As H 4-[2-(4-metilfenilsulfanil)-fenil]piperidina como inhibidor combinado de la recaptacion de serotonina y norepinefrina.
JP7179035B2 (ja) * 2006-06-16 2022-11-28 ハー・ルンドベック・アクチエゼルスカベット 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５－ＨＴ３および５－ＨＴ１Ａ活性を有する化合物としての１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
HRP20110412T1 (hr) 2006-06-16 2011-06-30 H. Lundbeck A/S Kristalni oblici 4-[2-4-(4-metilfenilsulfanil)fenil]piperidina sa kombiniranom inhibicijom reapsorpcije serotonina i norepinefrina za liječenje neuropatskih bolova
EP2439201B1 (en) * 2006-06-16 2013-08-07 H. Lundbeck A/S Compounds with combined sert, 5-ht3 and 5-ht1a activity
ZA200809917B (en) * 2006-06-16 2010-08-25 Lundbeck & Co As H Crystalline forms of 4- [2-(4-Methylphenylsulfanyl) - Phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
TWI405588B (zh) 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
TWI432194B (zh) * 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
WO2008151632A1 (en) 2007-06-15 2008-12-18 H.Lundbeck A/S 4- [2- (4-methylphenylsulfanyl) phenyl] piperidine for the treatment of irritable bowel syndrome (ibs)
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
AU2014200364B2 (en) * 2007-11-13 2015-09-17 H. Lundbeck A/S Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
WO2009081259A1 (en) * 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
UA98698C2 (en) 2008-03-03 2012-06-11 Х. Луннбек А/С Phenylsulfanylphenyl-piperidines and process for the preparation thereof
HRP20120920T1 (hr) 2008-11-14 2013-01-31 Theravance, Inc. Spojevi 4-[2-(2 fluorofenoksimetil)fenil]piperidina
TW201033181A (en) * 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
US8940746B2 (en) * 2009-04-24 2015-01-27 H. Lundbeck A/S Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]-piperazine
SG178325A1 (en) 2009-08-24 2012-03-29 Lundbeck & Co As H New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
CN102741226B (zh) * 2009-10-30 2016-01-06 詹森药业有限公司 4-取代的-2-苯氧基-苯胺δ阿片类受体调节剂
EP2523945A1 (en) 2010-01-11 2012-11-21 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
ES2543064T3 (es) * 2010-03-22 2015-08-14 Theravance Biopharma R&D Ip, Llc Compuestos de 1-(2-fenoximetilheteroaril)piperidina y piperazina
CA2797812C (en) * 2010-04-30 2018-02-20 Takeda Pharmaceutical Company Limited Enteric tablet
EP2564837B1 (en) 2010-04-30 2019-01-30 Takeda Pharmaceutical Company Limited Enteric tablet
EP2407467A1 (de) 2010-07-14 2012-01-18 Sandoz Ag Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure
TW201212918A (en) 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
EA024651B1 (ru) 2011-06-20 2016-10-31 Х. Лундбекк А/С Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении
CA2855640C (en) 2011-11-14 2020-03-10 The General Hospital Corporation Assays and methods for selecting a treatment regimen for a subject with depression
US9133144B2 (en) * 2012-01-03 2015-09-15 H. Lundbeck A/S Process for the manufacture of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine
CA2885266C (en) 2012-09-19 2020-05-12 Sandoz Ag Novel crystalline form of vortioxetine hydrobromide
KR102171152B1 (ko) 2012-12-13 2020-10-29 하. 룬드벡 아크티에셀스카브 보르티옥세틴 및 도네페질을 포함하는 조성물
AU2014220735B2 (en) 2013-02-22 2017-06-22 H. Lundbeck A/S Vortioxetine manufacturing process
EP3495347A1 (en) 2013-04-04 2019-06-12 LEK Pharmaceuticals d.d. New process for the synthesis of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine
CN104109135B (zh) * 2013-04-22 2018-10-26 江苏豪森药业集团有限公司 1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪的制备方法
IN2013MU03121A (enExample) 2013-09-30 2015-07-17 Cadila Healthcare Ltd
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CN104710345B (zh) * 2013-12-17 2017-09-05 江苏恩华药业股份有限公司 用于制备4‑（2‑（4‑甲基苯基硫基））苯基哌啶的化合物、其制备方法及应用
KR20160093025A (ko) 2013-12-20 2016-08-05 하. 룬트벡 아크티에 셀스카브 멜랑코리성 특색을 갖는 우울 장애의 치료를 위한 카파-활성을 갖는 오피오이드 수용체 길항제 및 보티옥세틴의 용도
EP2894154A1 (en) 2014-01-14 2015-07-15 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)aniline intermediates
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
WO2015114395A1 (en) 2014-01-31 2015-08-06 Egis Gyógyszergyár Zrt. Process for the preparation of vortioxetine salts
EP2930171A1 (en) 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104059030B (zh) * 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
FR3023320B1 (fr) * 2014-07-03 2017-03-10 Ifp Energies Now Systeme et procede de stockage et de recuperation d'energie par gaz comprime avec stockage de la chaleur au moyen d'un echangeur radial
CZ2014471A3 (cs) 2014-07-08 2016-01-20 Zentiva, K.S. Způsob přípravy vortioxetinu
US9687484B2 (en) 2014-07-18 2017-06-27 Dipharma Francis S.R.L. Crystalline forms of an antidepressant compound
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104292183B (zh) * 2014-09-29 2016-01-06 杨献美 一种抗抑郁药物沃替西汀的制备方法
WO2016079751A2 (en) 2014-11-17 2016-05-26 Megafine Pharma (P) Ltd. A process for preparation of vortioxetine and polymorphs thereof
EP3023417B1 (en) 2014-11-21 2017-06-28 Dipharma Francis S.r.l. Process for the preparation of an antidepressant and the intermediates thereof
CN104447622B (zh) * 2014-11-28 2017-01-04 郑州大明药物科技有限公司 氢溴酸沃替西汀β晶型的制备方法
CN104586756A (zh) * 2015-01-05 2015-05-06 万特制药(海南)有限公司 一种含沃替西汀的口服溶液及其制备方法
CZ201531A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Polymerem stabilizované amorfní formy vortioxetinu
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
WO2016125191A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Processes for the preparation of vortioxetine hydrobromide
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
AU2016224930A1 (en) 2015-02-25 2017-09-07 Lupin Limited Process for the preparation of Vortioxetine
WO2016151328A1 (en) 2015-03-26 2016-09-29 Cipla Limited Method for making serotonin reuptake inhibitors
CN104829557B (zh) * 2015-04-23 2017-06-27 山东百诺医药股份有限公司 一种新化合物1‑[2‑（2,4‑二甲基苯基硫基）苯基]‑2‑氧哌嗪及其制备方法和在沃替西汀合成中的应用
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
BR112018000841A8 (pt) * 2015-07-17 2022-11-22 Pasteur Institut Agente estimulante de receptor 5-hidroxitriptamina1b para uso como um promotor de auto-renovação e/ou diferenciação de células satélites
EP3337789A1 (en) * 2015-08-19 2018-06-27 Amneal Pharmaceuticals Company GmbH Process for preparation of vortioxetine hydrobromide
US20180303772A1 (en) * 2015-10-14 2018-10-25 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for the treatment of myocardial infarction
CN105461635B (zh) * 2015-11-18 2018-06-08 乳源瑶族自治县大众药品贸易有限公司 苯基哌嗪衍生物及其使用方法和用途
CN105348204B (zh) * 2015-11-18 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途
US11013830B2 (en) * 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
WO2018002115A1 (en) 2016-07-01 2018-01-04 H. Lundbeck A/S Vortioxetine dosing regimes for fast onset of antidepressant effect
JP2019524723A (ja) 2016-07-15 2019-09-05 アンスティテュ・パストゥール 皮膚および／または毛の修復のための５−ヒドロキシトリプタミン１ｂ受容体刺激剤
CA3031458A1 (en) * 2016-07-22 2018-01-25 Jiangsu Nhwaluokang Pharmaceutical Research And Development Co., Ltd. Vortioxetine analogue and use and preparation thereof
US20190224192A1 (en) 2016-08-29 2019-07-25 Cipla Limited Stable Pharmaceutical Composition of Vortioxetine Hydrobromide
CN106349132B (zh) * 2016-08-30 2018-02-02 重庆植恩药业有限公司 沃替西汀中间体杂质及其制备方法和用途
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN108409728B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
CN108409729B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
US10428033B2 (en) 2017-02-15 2019-10-01 Piramal Enterprises Limited Process for the preparation of vortioxetine and salts thereof
EP3582759A4 (en) 2017-02-17 2021-01-06 Unichem Laboratories Ltd BIOEQUIVALENT PHARMACEUTICAL COMPOSITION OF VORTIOXETINE BROMHYDRATE
EP3585388A4 (en) 2017-02-23 2020-08-12 Unichem Laboratories Ltd IMPROVED PROCESS FOR PREPARATION AND PURIFICATION OF VORTIOXETINE BROMHYDRATE
US11124491B2 (en) * 2017-04-25 2021-09-21 H. Lundbeck A/S Process for the manufacture of vortioxetine HBr alpha-form
EP3412661A1 (en) 2017-06-08 2018-12-12 Enantia, S.L. Cocrystals of vortioxetine hydrobromide and resorcinol
KR102026337B1 (ko) 2017-07-07 2019-09-27 영진약품 주식회사 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법
CN107915685A (zh) * 2017-12-11 2018-04-17 重庆植恩药业有限公司 一种氢溴酸沃替西汀中间体的制备方法
CN108017595A (zh) * 2017-12-20 2018-05-11 安徽源久源科技有限公司 一种1-[2-(2,5-二甲基苯硫基)苯基]哌嗪的制备方法
ES2976985T3 (es) 2018-06-20 2024-08-14 Vio Ag Pharmaceuticals S A Enfoque de activación C-H organo-pseudocatalítica de un recipiente para la preparación de vortioxetina y producto intermedio de vortioxetina
CN108863986B (zh) * 2018-08-06 2020-01-21 广东东阳光药业有限公司 二氟甲基取代的苯基哌嗪衍生物及其用途
CN108727393B (zh) * 2018-08-06 2019-10-29 广东东阳光药业有限公司 苯基二氮杂双环衍生物及其用途
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
WO2021198778A1 (en) 2020-04-03 2021-10-07 H. Lundbeck A/S 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine for prevention or treatment of emotional blunting
US12281088B2 (en) 2020-09-10 2025-04-22 Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd Process for the synthesis of vortioxetine
GB2622880A (en) 2022-09-30 2024-04-03 Alkaloid Ad Skopje Palatable orodispersible formulation of vortioxetine
WO2025132869A1 (en) 2023-12-21 2025-06-26 H. Lundbeck A/S Method for the preparation of vortioxetine pharmaceutical compositions with low amounts of nitrosamine impurities
CN120774863A (zh) * 2024-04-02 2025-10-14 王春刚 一种烷基二胺取代双芳杂环基硫醚类化合物及其制备和在制备治疗和/或预防肿瘤药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1489711A (en) 1975-07-21 1977-10-26 Science Union & Cie 1-phenoxyphenyl-piperazine derivatives process for their preparation and pharmaceutical compositions containing the
EP0755923A1 (en) 1995-01-23 1997-01-29 Suntory Limited Ameliorant or remedy for symptoms caused by ischemic diseases and compounds useful therefor
WO2001049678A1 (en) 1999-12-30 2001-07-12 H. Lundbeck A/S Substituted phenyl-piperazine derivatives, their preparation and use
WO2001049681A1 (en) 1999-12-30 2001-07-12 H. Lundbeck A/S A method for the preparation of substituted benzene derivatives

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS151752B1 (enExample) 1971-04-13 1973-11-19
CS151751B1 (enExample) 1971-04-13 1973-11-19
CS151755B1 (enExample) 1971-04-13 1973-11-19
CS151753B1 (enExample) 1971-04-13 1973-11-19
US4241071A (en) 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198417A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
US4198419A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenylthiophenylpiperidines
ES2004809A6 (es) 1987-07-29 1989-02-01 Ferrer Int Procedimiento de obtencion de nuevas 1-(2-(fenilmetil)fenil)piperazinas
GB9126311D0 (en) 1991-12-11 1992-02-12 Wellcome Found Substituted diphenylsulfides
CZ293595A3 (cs) 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
ES2241169T3 (es) * 1997-10-31 2005-10-16 Daiichi Suntory Pharma Co., Ltd. Derivados de arilpiperidinopropanol y arilpiperazinopropanol y productos farmaceuticos que los contienen.
EE200100514A (et) 1999-04-02 2002-12-16 Icos Corporation LFA-1 ICAM-idega seondumise inhibiitorid ja nendekasutamine
MXPA02001160A (es) 1999-08-04 2002-07-02 Millennium Pharm Inc Compuestos que se unen a los receptores para melanocortina-4, y metodo de uso de estos.
JP2003509294A (ja) * 1999-09-14 2003-03-11 ファーマコペイア インコーポレイテッド マルチチャネル分散ヘッドを含む物品
US6813639B2 (en) 2000-01-26 2004-11-02 Viaclix, Inc. Method for establishing channel-based internet access network
DE10033548C2 (de) 2000-07-11 2002-05-16 Wolfgang Papenbrock Verfahren zur Vorschau von Internetseiten
EP1370558B1 (en) * 2001-01-23 2005-08-24 Eli Lilly And Company Piperazine- and piperidine-derivatives as melanocortin receptor agonists
WO2002062766A2 (en) 2001-02-07 2002-08-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
CA2467118A1 (en) * 2001-12-20 2003-07-03 H. Lundbeck A/S Aryloxyphenyl and arylsulfanylphenyl derivatives
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
SI1626720T1 (sl) * 2003-04-04 2008-12-31 Lundbeck & Co As H Derivati 4-(2-fenilsulfanil-fenil)-piperidina kotzaviralci ponovnega vnosa serotonina
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
EP2439201B1 (en) * 2006-06-16 2013-08-07 H. Lundbeck A/S Compounds with combined sert, 5-ht3 and 5-ht1a activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1489711A (en) 1975-07-21 1977-10-26 Science Union & Cie 1-phenoxyphenyl-piperazine derivatives process for their preparation and pharmaceutical compositions containing the
EP0755923A1 (en) 1995-01-23 1997-01-29 Suntory Limited Ameliorant or remedy for symptoms caused by ischemic diseases and compounds useful therefor
WO2001049678A1 (en) 1999-12-30 2001-07-12 H. Lundbeck A/S Substituted phenyl-piperazine derivatives, their preparation and use
WO2001049681A1 (en) 1999-12-30 2001-07-12 H. Lundbeck A/S A method for the preparation of substituted benzene derivatives

Also Published As

Publication number Publication date
EP1436271A1 (en) 2004-07-14
JP3955614B2 (ja) 2007-08-08
BRPI0212733B8 (pt) 2021-05-25
US20140163043A1 (en) 2014-06-12
PL210551B1 (pl) 2012-02-29
US20070060574A1 (en) 2007-03-15
MEP6508A (xx) 2010-02-10
AU2006215994B2 (en) 2008-11-13
CA2462110E (en) 2003-04-10
AU2006215994A1 (en) 2006-10-05
IL160655A0 (en) 2004-07-25
EA200601269A1 (ru) 2007-02-27
EP1749818A2 (en) 2007-02-07
ME00039B (me) 2010-06-10
ATE386730T1 (de) 2008-03-15
NZ531556A (en) 2005-12-23
RS52326B (sr) 2012-12-31
AR036659A1 (es) 2004-09-22
ZA200401583B (en) 2005-05-25
US9090575B2 (en) 2015-07-28
ATE441631T1 (de) 2009-09-15
EA007537B1 (ru) 2006-10-27
HK1072600A1 (zh) 2005-09-02
NO2014011I1 (no) 2014-05-13
EG25095A (en) 2011-08-17
BE2014C036I2 (enExample) 2021-11-22
US7138407B2 (en) 2006-11-21
IS2732B (is) 2011-04-15
CY2014022I2 (el) 2015-12-09
CY1107924T1 (el) 2013-09-04
US10844029B2 (en) 2020-11-24
NO2014011I2 (no) 2015-08-31
US7144884B2 (en) 2006-12-05
WO2003029232A1 (en) 2003-04-10
NL300652I2 (enExample) 2016-01-18
AU2002333220A2 (en) 2003-04-14
PL209253B1 (pl) 2011-08-31
CY2014022I1 (el) 2015-12-09
NO20083446L (no) 2004-04-21
US20180127389A1 (en) 2018-05-10
UA81749C2 (uk) 2008-02-11
US20060084662A1 (en) 2006-04-20
RS52865B (sr) 2013-12-31
EA200400498A1 (ru) 2004-08-26
DE60225162D1 (de) 2008-04-03
US7148238B2 (en) 2006-12-12
DK1436271T6 (da) 2022-06-27
US9708280B2 (en) 2017-07-18
PL368442A1 (pl) 2005-03-21
JP2007031447A (ja) 2007-02-08
NO20041628L (no) 2004-04-21
EA007537B3 (ru) 2015-02-27
RS20120158A2 (sr) 2012-10-31
KR100770194B1 (ko) 2007-10-25
RS20120158A3 (en) 2013-10-31
KR100842702B1 (ko) 2008-07-01
IS7164A (is) 2004-02-26
NO326443B1 (no) 2008-12-08
DE60233608D1 (de) 2009-10-15
EP1749818B1 (en) 2009-09-02
CN1319958C (zh) 2007-06-06
LTC1436271I2 (lt) 2016-09-12
HUP0402313A2 (hu) 2005-02-28
EA011096B1 (ru) 2008-12-30
SI1436271T1 (sl) 2008-06-30
CO5580746A2 (es) 2005-11-30
BR0212733B1 (pt) 2014-05-13
BR122012023120B1 (pt) 2017-03-21
HRP20040220A2 (en) 2005-02-28
AU2002333220C1 (en) 2023-10-05
BR122012009534B1 (pt) 2018-02-27
MY140950A (en) 2010-02-12
BR122012009534B8 (pt) 2019-01-29
DE60225162T2 (de) 2009-02-12
ES2298425T7 (es) 2022-06-27
JP3896116B2 (ja) 2007-03-22
ES2298425T3 (es) 2008-05-16
US7683053B2 (en) 2010-03-23
EP1749818A3 (en) 2008-04-02
HUP0402313A3 (en) 2010-03-29
KR20060118020A (ko) 2006-11-17
AR066460A2 (es) 2009-08-19
CN1561336A (zh) 2005-01-05
DK1749818T3 (da) 2009-10-12
DK1436271T3 (da) 2008-06-09
CY1110064T1 (el) 2015-01-14
UA93857C2 (uk) 2011-03-25
CA2462110A1 (en) 2003-04-10
RS27704A (sr) 2006-10-27
BR122012009534C8 (pt) 2021-05-25
DE60225162T3 (de) 2022-08-11
US20050014740A1 (en) 2005-01-20
LU92397I2 (fr) 2014-05-12
US8110567B2 (en) 2012-02-07
NO332355B1 (no) 2012-09-03
AU2006215994A2 (en) 2006-10-05
IS2578B (is) 2010-02-15
HU228956B1 (en) 2013-07-29
FR14C0033I1 (enExample) 2014-06-13
US8476279B2 (en) 2013-07-02
HU230189B1 (hu) 2015-09-28
FR14C0033I2 (fr) 2014-11-14
AU2006215994A9 (en) 2006-10-05
US20160137620A1 (en) 2016-05-19
MXPA04002959A (es) 2004-07-05
NL300652I1 (enExample) 2016-01-18
AU2002333220B2 (en) 2008-02-07
KR20040047886A (ko) 2004-06-05
PT1749818E (pt) 2009-10-06
US20210276966A1 (en) 2021-09-09
BR0212733A (pt) 2004-11-16
US20120302553A1 (en) 2012-11-29
LTPA2014013I1 (lt) 2014-04-25
BR122012023120B8 (pt) 2022-01-18
EP1436271B1 (en) 2008-02-20
KR20070103515A (ko) 2007-10-23
IS8806A (is) 2009-03-10
PT1436271E (pt) 2008-04-10
EP1436271B3 (en) 2022-04-20
HUS1400012I1 (hu) 2020-12-28
JP2007051149A (ja) 2007-03-01
JP2005505585A (ja) 2005-02-24
JP3955613B2 (ja) 2007-08-08
US20110009423A1 (en) 2011-01-13
ES2328725T3 (es) 2009-11-17
US20060089368A1 (en) 2006-04-27
CA2462110C (en) 2010-05-11

Similar Documents

Publication Publication Date Title
KR100783346B1 (ko) 세로토닌 재흡수 억제제로서 페닐-피페라진 유도체
AU2002333220A1 (en) Phenyl-piperazine derivatives as serotonin reuptake inhibitors

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20061027

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20070110

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20070619

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20070110

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20070920

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20070619

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20071024

Appeal identifier: 2007101009957

Request date: 20070920

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20070927

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20070920

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20070920

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20070228

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20071024

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20071023

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20071203

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20071203

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20101124

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20111122

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20121123

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20121123

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20131119

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20131119

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20141118

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20141118

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20151030

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20151030

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20161028

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20161028

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20171027

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20171027

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20201028

Start annual number: 14

End annual number: 14

PR1001 Payment of annual fee

Payment date: 20211027

Start annual number: 15

End annual number: 15

PC1801 Expiration of term

Termination date: 20230402

Termination category: Expiration of duration